7). From a clinical perspective, the pharmacological action of CU06-1004 can be applied to prevent the no-reflow phenomenon, which is a major therapeutic target to improve the clinical outcomes of AMI patients42. Fig. 7: Schematic diagram of the underlying therapeutic mechanisms of CU06-1004....